08:32 AM EDT, 07/10/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Wednesday a phase 2/3 trial has shown that its investigational brain disease treatment, paxalisib, causes clinically significant improvement in overall survival for patients with glioblastoma, a life-threatening brain cancer.

Paxalisib showed an approximate 33% improvement in the overall survival of newly diagnosed patients with glioblastoma, compared with standard of care, Kazia said.

A prespecified secondary analysis showed that the median overall survival of 54 paxalisib-treated patients was 15.54 months, while the standard-of-care arm with 46 patients had a median of 11.89 months.

Shares of the company rose 11% in recent Wednesday premarket activity.

Price: 0.2130, Change: +0.02, Percent Change: +10.94